Medifast, Inc. (MED) Financial Ratios
30 years of historical data (1996–2025) · Consumer Cyclical · Personal Products & Services
EV/EBITDA
↓
N/A
—
5yr avg: 7.36
30Y Low1.9·High69.5
P/FCF
↑
112.97
↑+256% vs avg
5yr avg: 31.75
30Y Low2.9·High128.1
P/B Ratio
↓
0.70
↓-86% vs avg
5yr avg: 5.15
30Y Low0.6·High14.8
ROE
↓
-9.1%
↑-121% vs avg
5yr avg: 43.8%
30Y Low-330%·High261%
Debt/EBITDA
↑
N/A
—
5yr avg: 0.37
30Y Low0.0·High2.6
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
MED Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Medifast, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis. On a free-cash-flow basis, the stock trades at 113.0x P/FCF, 256% above the 5-year average of 31.8x.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $141M | $117M | $193M | $734M | $1.3B | $2.5B | $2.3B | $1.3B | $1.5B | $844M | $497M |
| Enterprise Value | $69M | $45M | $118M | $662M | $1.2B | $2.4B | $2.2B | $1.3B | $1.4B | $769M | $446M |
| P/E Ratio → | -7.46 | — | 92.74 | 7.39 | 9.06 | 15.08 | 22.62 | 17.04 | 27.06 | 30.48 | 27.94 |
| P/S Ratio | 0.37 | 0.30 | 0.32 | 0.68 | 0.81 | 1.62 | 2.49 | 1.86 | 3.01 | 2.80 | 1.81 |
| P/B Ratio | 0.70 | 0.59 | 0.92 | 3.64 | 8.39 | 12.22 | 14.80 | 12.67 | 13.84 | 7.77 | 5.18 |
| P/FCF | 112.97 | 93.90 | 11.35 | 5.20 | 7.31 | 41.00 | 16.70 | 17.89 | 27.03 | 21.10 | 22.13 |
| P/OCF | 20.56 | 17.09 | 7.89 | 4.97 | 6.68 | 26.17 | 16.02 | 15.76 | 24.83 | 19.52 | 19.62 |
P/E links to full P/E history page with 30-year chart
MED EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 0.12 | 0.20 | 0.62 | 0.78 | 1.57 | 2.33 | 1.77 | 2.85 | 2.55 | 1.62 |
| EV / EBITDA | — | — | 7.59 | 4.74 | 6.33 | 10.77 | 15.70 | 13.22 | 19.44 | 17.54 | 13.81 |
| EV / EBIT | — | — | 41.13 | 5.23 | 6.71 | 11.11 | 16.21 | 13.89 | 20.69 | 19.40 | 16.59 |
| EV / FCF | — | 35.84 | 6.95 | 4.69 | 6.97 | 39.82 | 15.61 | 17.04 | 25.57 | 19.22 | 19.83 |
MED Profitability
Margins and return-on-capital ratios measuring operating efficiency
Medifast, Inc. earns an operating margin of -3.7%, below the Consumer Cyclical sector average of 2.9%. Operating margins have compressed from 11.8% to -3.7% over the past 3 years, signaling potential cost pressures or competitive headwinds. A negative ROE of -9.1% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 71.3% | 71.3% | 73.8% | 72.4% | 71.3% | 73.9% | 74.6% | 75.2% | 75.8% | 75.5% | 74.9% |
| Operating Margin | -3.7% | -3.7% | 0.5% | 11.8% | 11.6% | 14.2% | 14.4% | 12.8% | 13.8% | 13.1% | 9.8% |
| Net Profit Margin | -4.8% | -4.8% | 0.3% | 9.3% | 9.0% | 10.7% | 11.0% | 10.9% | 11.1% | 9.2% | 6.5% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -9.1% | -9.1% | 1.0% | 55.8% | 80.3% | 91.2% | 78.5% | 72.8% | 51.3% | 27.1% | 19.3% |
| ROA | -6.9% | -6.9% | 0.7% | 31.8% | 40.2% | 48.6% | 43.7% | 42.8% | 35.4% | 20.8% | 15.0% |
| ROIC | -8.1% | -8.1% | 1.6% | 85.2% | 123.6% | 239.3% | 436.1% | 197.3% | 169.1% | 76.3% | 44.2% |
| ROCE | -6.5% | -6.5% | 1.3% | 64.3% | 91.5% | 110.0% | 95.8% | 81.2% | 63.4% | 38.6% | 28.2% |
MED Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $89M exceeds total debt of $17M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.08 | 0.08 | 0.08 | 0.11 | 0.17 | 0.16 | 0.07 | 0.13 | — | — | 0.01 |
| Debt / EBITDA | — | — | 1.03 | 0.16 | 0.13 | 0.15 | 0.08 | 0.14 | — | — | 0.02 |
| Net Debt / Equity | — | -0.36 | -0.36 | -0.36 | -0.40 | -0.35 | -0.97 | -0.60 | -0.75 | -0.69 | -0.54 |
| Net Debt / EBITDA | — | — | -4.80 | -0.52 | -0.31 | -0.32 | -1.10 | -0.66 | -1.11 | -1.71 | -1.60 |
| Debt / FCF | — | -58.06 | -4.39 | -0.51 | -0.35 | -1.19 | -1.10 | -0.85 | -1.46 | -1.88 | -2.30 |
| Interest Coverage | — | — | — | — | 263.57 | — | — | — | — | — | — |
Net cash position: cash ($89M) exceeds total debt ($17M)
MED Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Medifast, Inc.'s current ratio of 4.69x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The quick ratio of 4.22x is notably lower than the current ratio, indicating a significant portion of current assets is tied up in inventory. The current ratio has improved from 2.43x to 4.69x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 4.69 | 4.69 | 3.34 | 2.43 | 1.58 | 1.81 | 2.10 | 1.94 | 2.41 | 3.37 | 4.15 |
| Quick Ratio | 4.22 | 4.22 | 2.68 | 1.84 | 0.74 | 0.75 | 1.62 | 1.33 | 1.77 | 2.85 | 3.40 |
| Cash Ratio | 3.89 | 3.89 | 2.53 | 1.63 | 0.62 | 0.65 | 1.57 | 1.17 | 1.67 | 2.66 | 3.15 |
| Asset Turnover | — | 1.50 | 2.12 | 3.46 | 5.06 | 3.83 | 3.39 | 3.67 | 2.96 | 2.07 | 2.26 |
| Inventory Turnover | 5.47 | 5.47 | 3.72 | 5.43 | 3.85 | 2.21 | 4.44 | 3.63 | 3.11 | 3.82 | 3.76 |
| Days Sales Outstanding | — | — | — | — | — | — | 0.23 | 0.73 | 0.74 | 0.70 | 1.84 |
MED Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Medifast, Inc. returns 0.4% to shareholders annually — split between a 0.1% dividend yield and 0.3% buyback yield.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | 0.1% | 0.2% | 0.4% | 9.9% | 5.5% | 2.6% | 2.3% | 2.7% | 1.5% | 1.8% | 2.4% |
| Payout Ratio | — | — | 34.2% | 73.4% | 49.9% | 38.9% | 51.7% | 45.4% | 41.5% | 55.5% | 66.7% |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | 1.1% | 13.5% | 11.0% | 6.6% | 4.4% | 5.9% | 3.7% | 3.3% | 3.6% |
| FCF Yield | 0.9% | 1.1% | 8.8% | 19.2% | 13.7% | 2.4% | 6.0% | 5.6% | 3.7% | 4.7% | 4.5% |
| Buyback Yield | 0.3% | 0.3% | 0.4% | 0.9% | 9.8% | 2.5% | 0.2% | 3.6% | 2.0% | 0.3% | 0.3% |
| Total Shareholder Yield | 0.4% | 0.5% | 0.8% | 10.9% | 15.3% | 5.1% | 2.5% | 6.2% | 3.6% | 2.1% | 2.7% |
| Shares Outstanding | — | $11M | $11M | $11M | $11M | $12M | $12M | $12M | $12M | $12M | $12M |
Peer Comparison
Compare MED with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 MEDYou | $141M | -7.5 | — | 113.0 | 71.3% | -3.7% | -9.1% | -8.1% | — |
 HIMS | $7B | 52.7 | 44.5 | 93.8 | 59.3% | 5.2% | 25.2% | 10.7% | 6.4 |
 NUS | $354M | 2.3 | 6.0 | 7.7 | 69.4% | 4.4% | 22.0% | 5.5% | 4.3 |
 USNA | $369M | 34.5 | 2.5 | 43.3 | 78.3% | 5.5% | 1.8% | 8.6% | 0.2 |
 RVLV | $1B | 23.5 | 15.0 | 30.0 | 53.5% | 6.1% | 13.0% | 23.5% | 0.4 |
 WW | $118M | 0.1 | 3.7 | — | 71.8% | 6.5% | 332.0% | 7.4% | 4.1 |
 HLF | $2B | 7.5 | 6.6 | 6.7 | 75.6% | 8.8% | — | 24.3% | 4.2 |
 PLNT | $5B | 32.0 | 15.7 | 28.1 | 52.0% | 27.4% | — | 12.0% | 5.3 |
 XPOF | $247M | -4.5 | 7.9 | 10.0 | 75.6% | 25.3% | — | 75.0% | 5.7 |
 NTRB | $48M | -1.5 | — | — | 25.7% | -408.4% | -125.6% | -270.2% | — |
 AMZN | $3.0T | 38.3 | 20.7 | 384.3 | 50.3% | 11.2% | 22.3% | 14.7% | 1.0 |
| Consumer Cyclical Median | — | 19.6 | 11.4 | 15.0 | 36.9% | 2.9% | 5.6% | 5.8% | 4.4 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 30 years · Updated daily
See MED's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs MED Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare MED vs HIMS
Side-by-side business, growth, and profitability comparison vs Hims & Hers Health, Inc..
Start ComparisonMED — Frequently Asked Questions
Quick answers to the most common questions about buying MED stock.
What is Medifast, Inc.'s P/E ratio?
Medifast, Inc.'s current P/E ratio is -7.5x. The historical average is 25.0x.
What is Medifast, Inc.'s ROE?
Medifast, Inc.'s return on equity (ROE) is -9.1%. The historical average is 19.5%.
Is MED stock overvalued?
Based on historical data, Medifast, Inc. is trading at a P/E of -7.5x. Compare with industry peers and growth rates for a complete picture.
What is Medifast, Inc.'s dividend yield?
Medifast, Inc.'s current dividend yield is 0.14%.
What are Medifast, Inc.'s profit margins?
Medifast, Inc. has 71.3% gross margin and -3.7% operating margin.